Scientific Article
previous document  unige:11366  next document
add to browser collection

Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model

Jordan, M. B.
van Rooijen, Nico
Kappler, John
Marrack, Philippa
Published in Blood. 2003, vol. 101, no. 2, p. 594-601
Abstract Autoimmune hemolytic anemia (AIHA) is a disease in which autoantibodies against red blood cells (RBCs) lead to their premature destruction. Most clinically significant autoantibodies are of the immunoglobulin G (IgG) type, which leads primarily to the uptake and destruction of RBCs by splenic and hepatic macrophages. Therapies such as corticosteroids and splenectomy are directed at interfering with this process. Liposomally encapsulated clodronate (dichloromethylene diphosphonate) has previously been found to be a potent antimacrophage agent. It selectively depletes animals of macrophages within 24 hours of administration by inducing apoptosis in these cells. Therefore, we hypothesized that liposomal clodronate would be a useful agent for treating AIHA. We tested this hypothesis in a mouse model of AIHA in which animals were given either anti-RBC antibodies or preopsonized RBCs. In either case, liposomal clodronate substantially decreased RBC destruction. This drug formulation was effective within hours by first blocking and then depleting phagocytic macrophages, and its action lasted for 1 to 2 weeks. Thus, in AIHA, liposomal clodronate therapy may act like a temporary, medicinal splenectomy. As such, it may prove useful in situations where rapid response to therapy is critical or other medical therapies are inadequate.
Keywords Anemia, Hemolytic, Autoimmune/ drug therapyAnimalsAntibodies, MonoclonalClodronic Acid/ administration & dosage/therapeutic useDose-Response Relationship, DrugDrug Evaluation, PreclinicalErythrocytes/immunologyLiposomes/therapeutic useMacrophages/drug effects/immunologyMiceModels, AnimalPhagocytosis/drug effectsTreatment Outcome
PMID: 12393630
Full text
(ISO format)
JORDAN, M. B. et al. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. In: Blood, 2003, vol. 101, n° 2, p. 594-601. doi: 10.1182/blood-2001-11-0061

308 hits

0 download


Deposited on : 2010-08-27

Export document
Format :
Citation style :